C L I N I C A L S T U D Y S U M M A R Y

More documents

Recommendations

Info

151557_GreenLightSummary_B 5/31/07 4:29 PM Page 24G R E E N L I G H TC L I N I C A L S T U D Y S U M M A R YSubjective and objective 24-month follow ups in patients with (RUR) and without (NUR) before PVPCharacteristics Preoperatively Discharge Postoperatively (mos.)1 3 6 12 24RURPatients (n) 70 68 49 42 31 29 16IPSS 15.5±6.6 9.3±7.2* 7.6±5.0 ns 7.0±3.9 ns 5.7±4.4 ns 5.5±4.2 ns 4.4±2.7 nsIPSS-QOL 3.5±2.0 1.8±1.7 § 1.4±1.1 ns 1.1±1.3 ns 0.8±0.7 ns 1.0±1.1 ns 0.9±0.9 nsQmax (mL/s) — 13.7±10.7* 16.9±10.2 # 16.3±5.7 ns 17.7±9.4 ns 18.2±11.8 ns 19.4±6.2 nsVres (mL) 318±293 80±156 § 29±41 § 26±48 ns 47±68 ns 39±53 ns 38±52 nsNURPatients (n) 113 109 89 73 67 55 19IPSS 18.6±6.2 9.9±6.4* 10.7±7.9ns 7.5±5.9* 6.2±4.8ns 6.5±5.4ns 6.5±5.8nsIPSS-QOL 3.5±1.7 1.8±1.5* 1.9±1.6ns 1.3±1.4 § 1.1±1.1ns 1.1±1.1ns 1.2±1.1nsQmax (mL/s) 7.1±3.1 15.1±9.4* 19.4±10.9 § 20.9±9.4 # 19.7±9.1ns 21.0±9.4ns 23.3±9.4nsVres (mL) 154±153 80±108* 27±45* 24±33ns 26±44ns 30±40ns 23±27nsData presented as mean standard deviation. Statistical comparison to the previous control, Wilcoxon test, SPSS 11.5; p value
151557_GreenLightSummary_B 5/31/07 4:29 PM Page 25G R E E N L I G H TC L I N I C A L S T U D Y S U M M A R YHigh power (80 W) potassium-titanyl-phosphate laser vaporizationof the prostate in 66 high risk patientsReich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser TDepartment of Urology, University-Hospital Grosshadern, Ludwig-Maximilians-University Munich, Munich Germany and Depart ofUrology, University-Hospital Basel (AB, TS) Basel, SwitzerlandJ Urol Jan 2005;173:158-160Purpose: Men with lower urinary tract symptomssecondary to benign prostatic hyperplasia who are at highcardiopulmonary risk or on oral anticoagulation are oftendenied surgical treatment. Potassium-titanyl-phosphate(KTP) laser vaporization at 80 W is a novel, rapidly emergingtechnique that promises instant hemostatic tissue ablation.We evaluated the merits of this procedure in patients athigh risk and those on long-term anticoagulation.Materials and Methods: The prospective study included66 patients with sever lower urinary tract symptoms whounderwent 80 W KTP laser vaporization of the prostate.All patients were at high cardiopulmonary risk, havingpresented with an American Society of Anesthesiologyscore of 3 or greater. Additionally, 29 patients were beingtreated with ongoing oral anticoagulant therapy (26) orhad a severe bleeding disorder (3).Results: In all 66 patients KTP laser vaporization wasperformed successfully. Mean preoperative prostate volume± SD was 49 ± 30mL and mean operative time was 49 ± 19minutes. No major complication occurred intraoperativelyor postoperatively and no blood transfusions was required.Postoperatively 48 of 62 catheterized patients (77%) did notrequire irrigation. Average catheterization time was 1.8 ± 1.4days. Two patients required reoperation due to recurrenturinary retention. At 1, 3, 6 and 12 months mean urinarypeak flow increased from 6.7 ± 2 mL per secondpreoperatively to 18.5 ± 9, 18.9 ± 10, 19.2 ± 8 and 21.6 ± 7mL per second, respectively. Mean International ProstateSymptom Score decreased from 20.2 ± 6 to 11.7 ± 7, 7.9 + 7,6.9 ± 5 and 6.5 ± 4, respectively.Subjective and objective outcomes of high power KTP laser vaporizationBaseline 1 mo. 3 mos. 6 mos. 12 mos.No. pts. 66 66 66 62 51Qmax (mL/sec):Mean±SD 6.7±2* 18.5±9 18.9±10 19.2±8 21.6±7% Change — 176 182 187 222p Value (Wilcoxon test) —
Page 1 and 2: 151557_GreenLightSummary_B 5/31/07
Page 23: 151557_GreenLightSummary_B 5/31/07

C L I N I C A L S T U D Y S U M M A R Y

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?